Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 20 of 20 entries

Molecular Profile	Indication/Tumor Type	Response Type	Relevant Treatment Approaches	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
FGFR2 C382R	cholangiocarcinoma	predicted - sensitive	FGFR2 Inhibitor	Pemigatinib	Case Reports/Case Series	Actionable	In a Phase I trial (FIGHT-101), Pemazyre (pemigatinib) treatment led to a partial response in a cholangiocarcinoma patient harboring FGFR2 C382R (PMID: 35176457; NCT02393248).	35176457
FGFR2 C382R	intrahepatic cholangiocarcinoma	predicted - sensitive	FGFR2 Inhibitor	Pemigatinib	Case Reports/Case Series	Actionable	In a clinical case study, Pemazyre (pemigatinib) treatment resulted in complete metabolic remission in a patient with metastatic intrahepatic cholangiocarcinoma harboring FGFR2 C382R (PMID: 36188486).	36188486
FGFR2 C382R	cholangiocarcinoma	predicted - sensitive	FGFR2 Inhibitor	Pemigatinib	Case Reports/Case Series	Actionable	In a Phase II trial (FIGHT-207), Pemazyre (pemigatinib) treatment demonstrated safety in previously treated patients with advanced solid tumors harboring an activating non-kinase domain mutation in FGFR1, FGFR2, or FGFR3, and resulted in an objective response rate of 9.4% (3/32, partial responses), including a partial response with a progression-free survival of 6.0 months in a patient with cholangiocarcinoma harboring FGFR2 C382R (PMID: 38710951; NCT03822117).	38710951
FGFR2 C382R	endometrial cancer	predicted - sensitive	FGFR Inhibitor (Pan)	Erdafitinib	Case Reports/Case Series	Actionable	In a Phase II trial (RAGNAR), treatment with Balversa (erdafitinib) resulted in partial response in two patients with endometrial cancer harboring FGFR2 C382R, with a duration of response of 23.72 months and 2.79 months, respectively (PMID: 37541273; NCT04083976).	37541273
FGFR2 C382R	breast cancer	predicted - sensitive	FGFR Inhibitor (Pan)	Erdafitinib	Case Reports/Case Series	Actionable	In a Phase II trial (RAGNAR), treatment with Balversa (erdafitinib) resulted in a partial response with a duration of response of 14.32 months in a patient with breast cancer harboring FGFR2 C382R (PMID: 37541273; NCT04083976).	37541273
FGFR2 C382R	cholangiocarcinoma	predicted - sensitive	FGFR Inhibitor (Pan)	Erdafitinib	Case Reports/Case Series	Actionable	In a Phase II trial (RAGNAR), treatment with Balversa (erdafitinib) resulted in a partial response with a duration of response of 15.11 months in a patient with cholangiocarcinoma harboring FGFR2 C382R (PMID: 37541273; NCT04083976).	37541273
FGFR2 C382R	head and neck squamous cell carcinoma	predicted - sensitive	FGFR Inhibitor (Pan)	Erdafitinib	Case Reports/Case Series	Actionable	In a Phase II trial (RAGNAR), treatment with Balversa (erdafitinib) resulted in a partial response with a duration of response of 2.79 months in a patient with squamous cell head and neck cancer harboring FGFR2 C382R (PMID: 37541273; NCT04083976).	37541273
FGFR2 C382R	cholangiocarcinoma	predicted - sensitive	FGFR2 Inhibitor	Tinengotinib	Case Reports/Case Series	Actionable	In a Phase I trial, Tinengotinib (TT-00420) treatment was well tolerated and resulted in stable disease in 53.3% (23/43) and partial response in 16.3% (7/43) of patients with advanced solid tumors, including a partial response in a patient with cholangiocarcinoma harboring FGFR2 C382R (PMID: 38297981; NCT03654547).	38297981
FGFR2 C382R	intrahepatic cholangiocarcinoma	predicted - sensitive	FGFR Inhibitor (Pan)	Erdafitinib	Case Reports/Case Series	Actionable	In a clinical case study, Balversa (erdafitinib) treatment resulted in a partial response with a progression-free survival of 9.3 months and best objective response of -67% in a patient with intrahepatic cholangiocarcinoma harboring FGFR2 C382R (reported as C383R) (PMID: 39226398).	39226398
FGFR2 C382R	intrahepatic cholangiocarcinoma	predicted - sensitive	FGFR Inhibitor (Pan)	Futibatinib	Case Reports/Case Series	Actionable	In a clinical case study, Lytgobi (futibatinib) treatment resulted in a partial response with a progression-free survival of 17.3 months and a best objective response of -53% in a patient with intrahepatic cholangiocarcinoma harboring FGFR2 C382R (reported as C383R) (PMID: 39226398).	39226398
FGFR2 C382R	triple-receptor negative breast cancer	predicted - sensitive	FGFR Inhibitor (Pan)	Erdafitinib	Case Reports/Case Series	Actionable	In a clinical case study, Balversa (erdafitinib) treatment resulted in a partial response with a progression-free survival of 24.3 months and best objective response of -59% in a patient with a triple-negative breast cancer harboring FGFR2 C382R (reported as C383R) (PMID: 39226398).	39226398
FGFR2 C382R	Advanced Solid Tumor	predicted - sensitive	FGFR2 Inhibitor	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 C382R were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 C382R	Advanced Solid Tumor	predicted - sensitive	FGFR Inhibitor (Pan)	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 C382R were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 C382R	Advanced Solid Tumor	predicted - sensitive	FGFR Inhibitor (Pan)	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 C382R were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 C382R	Advanced Solid Tumor	predicted - sensitive	FGFR Inhibitor (Pan)	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 C382R were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 C382R	Advanced Solid Tumor	predicted - sensitive	FGFR2 Inhibitor	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 C382R were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 C382R	Advanced Solid Tumor	predicted - resistant	FGFR Inhibitor (Pan)	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 C382R were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 C382R	breast cancer	predicted - sensitive	FGFR2 Inhibitor	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited growth of mouse mammary epithelial cells expressing FGFR2 C287R (corresponding to C382R in human) in culture (PMID: 35948633).	35948633
FGFR2 C382R	breast cancer	predicted - sensitive	FGFR2 Inhibitor	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Pemazyre (pemigatinib) inhibited growth of mouse mammary epithelial cells expressing FGFR2 C287R (corresponding to C382R in human) in culture (PMID: 35948633).	35948633
FGFR2 C382R	cholangiocarcinoma	no benefit	FGFR Inhibitor (Pan)	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Truseltiq (infigratinib) did not decrease viability of a cholangiocarcinoma cell line expressing FGFR2 C382R in culture (PMID: 37964396).	37964396

Showing 1 to 20 of 20 entries

Filter rows:

Profile Name	FGFR2 C382R
Gene Variant Detail	FGFR2 C382R (gain of function)
Relevant Treatment Approaches	FGFR Inhibitor (Pan) FGFR2 Inhibitor

Molecular Profile Detail

Contact

Filtering

Sorting